Evgen Pharma CEO Huw Jones tells Proactive the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases is in 'deep planning mode' for its two upcoming clinical trials. Jones also discusses its two recent academic collaborations to treat brain cancer and colorectal cancer, and commented on the group's current financial situation, including £9 million that exists on the balance sheet.
Evgen Pharma talks through clinical milestones and financial results from its 2022 full year report
